Molecular mechanisms of TLR2-Mediated antigen cross-presentation in dendritic cells

Journal of Immunology

Volumn 192, Issue 9, 2014, Pages 4233-4241

  Shen, Kuan Yin ^a,b   Song, Ying Chyi ^b   Chen, I Hua ^b   Leng, Chih Hsiang ^b,c   Chen, Hsin Wei ^b,c   Li, Hui Ju ^b   Chong, Pele ^b,c   Liu, Shih Jen ^a,b,c  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CLATHRIN; EARLY ENDOSOME ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 88; PEPTIDE DERIVATIVE; PEPTIDE VACCINE; RAB7 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CONTROLLED STUDY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENDOCYTOSIS; ENDOSOME; IN VITRO STUDY; INTERNALIZATION; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR REGRESSION; UPREGULATION;

ANIMALS; BLOTTING, WESTERN; CROSS-PRIMING; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; NEOPLASMS, EXPERIMENTAL; RAB GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTOR 2;

EID: 84899567400     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302850     Document Type: Article

References (49)

1. Flinsenberg, T. W., E. B. Compeer, J. J. Boelens, and M. Boes. 2011. Antigen cross-presentation: Extending recent laboratory findings to therapeutic intervention. Clin. Exp. Immunol. 165: 8-18
2. Monu, N., and E. S. Trombetta. 2007. Cross-talk between the endocytic pathway and the endoplasmic reticulum in cross-presentation by MHC class I molecules. Curr. Opin. Immunol. 19: 66-72
3. Guermonprez, P., L. Saveanu, M. Kleijmeer, J. Davoust, P. Van Endert, and S. Amigorena. 2003. ER-phagosome fusion defines an MHC class I crosspresentation compartment in dendritic cells. Nature 425: 397-402
4. Shen, L., L. J. Sigal, M. Boes, and K. L. Rock. 2004. Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo. Immunity 21: 155-165
5. Shen, L., and K. L. Rock. 2006. Priming of T cells by exogenous antigen crosspresented on MHC class I molecules. Curr. Opin. Immunol. 18: 85-91
6. Firat, E., L. Saveanu, P. Aichele, P. Staeheli, J. Huai, S. Gaedicke, A. Nil, G. Besin, B. Kanzler, P. Van Endert, and G. Niedermann. 2007. The role of endoplasmic reticulum-associated aminopeptidase 1 in immunity to infection and in cross-presentation. J. Immunol. 178: 2241-2248
7. Merzougui, N., R. Kratzer, L. Saveanu, and P. Van Endert. 2011. A proteasomedependent, TAP-independent pathway for cross-presentation of phagocytosed antigen. EMBO Rep. 12: 1257-1264
8. Burgdorf, S., C. Schölz, A. Kautz, R. Tampé, and C. Kurts. 2008. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat. Immunol. 9: 558-566
9. Kovacsovics-Bankowski, M., and K. L. Rock. 1995. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267: 243-246
10. Mant, A., F. Chinnery, T. Elliott, and A. P. Williams. 2012. The pathway of cross-presentation is influenced by the particle size of phagocytosed antigen. Immunology 136: 163-175
11. Chatterjee, B., A. Smed-Sörensen, L. Cohn, C. Chalouni, R. Vandlen, B. C. Lee, J. Widger, T. Keler, L. Delamarre, and I. Mellman. 2012. Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood 120: 2011-2020
12. Tacken, P. J., W. Ginter, L. Berod, L. J. Cruz, B. Joosten, T. Sparwasser, C. G. Figdor, and A. Cambi. 2011. Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. Blood 118: 4111-4119
13. Delamarre, L., M. Pack, H. Chang, I. Mellman, and E. S. Trombetta. 2005. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science 307: 1630-1634
14. Wagner, C. S., and P. Cresswell. 2012. TLR and nucleotide-binding oligomerization domain-like receptor signals differentially regulate exogenous antigen presentation. J. Immunol. 188: 686-693
15. De Brito, C., M. Tomkowiak, R. Ghittoni, C. Caux, Y. Leverrier, and J. Marvel. 2011. CpG promotes cross-presentation of dead cell-associated antigens by pre-CD8a+ dendritic cells [corrected]. J. Immunol. 186: 1503-1511
16. Oh, J. Z., and R. M. Kedl. 2010. The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate vaccine for eliciting cellular immunity. J. Immunol. 185: 4602-4608
17. Simmons, D. P., D. H. Canaday, Y. Liu, Q. Li, A. Huang, W. H. Boom, and C. V. Harding. 2010. Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9. J. Immunol. 185: 2405-2415
18. Gahéry-Ségard, H., G. Pialoux, B. Charmeteau, S. Sermet, H. Poncelet, M. Raux, A. Tartar, J. P. Lévy, H. Gras-Masse, and J. G. Guillet. 2000. Multiepitopic B-and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J. Virol. 74: 1694-1703
19. Andrieu, M., E. Loing, J. F. Desoutter, F. Connan, J. Choppin, H. Gras-Masse, D. Hanau, A. Dautry-Varsat, J. G. Guillet, and A. Hosmalin. 2000. Endocytosis of an HIV-derived lipopeptide into human dendritic cells followed by class Irestricted CD8(+) T lymphocyte activation. Eur. J. Immunol. 30: 3256-3265
20. Chen, H-W., S-J. Liu, H-H. Liu, Y. Kwok, C-L. Lin, L-H. Lin,M-Y. Chen, J-P. Tsai, L-S. Chang, F-F. Chiu, et al. 2009. A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design. Vaccine 27: 1400-1409
21. Xu, D. H., C. H. Zhou, Y. P. Xia, Z. Y. Qiu, Y. Z. Wu, Z. C. Jia, and W. Zhou. 2007. Cytotoxic T lymphocyte response induced by an improved synthetic lipopeptide vaccine against cervical cancer. Acta Pharmacol. Sin. 28: 695-702
22. Baz, A., K. Buttigieg, W. Zeng, M. Rizkalla, D. C. Jackson, P. Groves, and A. Kelso. 2008. Branched and linear lipopeptide vaccines have different effects on primary CD4+ and CD8+ T-cell activation but induce similar tumorprotective memory CD8+ T-cell responses. Vaccine 26: 2570-2579
23. Vitiello, A., G. Ishioka, H. M. Grey, R. Rose, P. Farness, R. LaFond, L. Yuan, F. V. Chisari, J. Furze, R. Bartholomeuz, et al. 1995. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Invest. 95: 341-349
24. Salmon-Céron, D., C. Durier, C. Desaint, L. Cuzin, M. Surenaud, N. B. Hamouda, J. D. Lelièvre, B. Bonnet, G. Pialoux, I. Poizot-Martin, et al; ANRS VAC18 trial group. 2010. Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: A phase 2 placebo-controlled ANRS trial. AIDS 24: 2211-2223
25. Pialoux, G., R. P. Quercia, H. Gahery, N. Daniel, L. Slama, P. M. Girard, P. Bonnard, W. Rozenbaum, V. Schneider, D. Salmon, and J. G. Guillet. 2008. Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: The LIPTHERA study. Clin. Vaccine Immunol. 15: 562-568
26. Gahery, H., S. Figueiredo, C. Texier, S. Pouvelle-Moratille, L. Ourth, C. Igea, M. Surenaud, J. G. Guillet, and B. Maillere. 2007. HLA-DR-restricted peptides identified in the Nef protein can induce HIV type 1-specific IL-2/IFN-gammasecreting CD4+ and CD4+ /CD8+ T cells in humans after lipopeptide vaccination. AIDS Res. Hum. Retroviruses 23: 427-437
27. Steller, M. A., K. J. Gurski, M. Murakami, R. W. Daniel, K. V. Shah, E. Celis, A. Sette, E. L. Trimble, R. C. Park, and F. M. Marincola. 1998. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin. Cancer Res. 4: 2103-2109
28. Houde, M., S. Bertholet, E. Gagnon, S. Brunet, G. Goyette, A. Laplante, M. F. Princiotta, P. Thibault, D. Sacks, and M. Desjardins. 2003. Phagosomes are competent organelles for antigen cross-presentation. Nature 425: 402-406
29. Lakadamyali, M., M. J. Rust, and X. Zhuang. 2006. Ligands for clathrinmediated endocytosis are differentially sorted into distinct populations of early endosomes. Cell 124: 997-1009
30. Porgador, A., J. W. Yewdell, Y. Deng, J. R. Bennink, and R. N. Germain. 1997. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6: 715-726
31. Bertram, E. M., R. G. Hawley, and T. H. Watts. 2002. Overexpression of rab7 enhances the kinetics of antigen processing and presentation with MHC class II molecules in B cells. Int. Immunol. 14: 309-318
32. Farhat, K., S. Riekenberg, H. Heine, J. Debarry, R. Lang, J. Mages, U. Buwitt-Beckmann, K. Röschmann, G. Jung, K. H. Wiesmuller, and A. J. Ulmer. 2008. Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling. J. Leukoc. Biol. 83: 692-701
33. Leng, C. H., H. W. Chen, L. S. Chang, H. H. Liu, H. Y. Liu, Y. P. Sher, Y. W. Chang, S. P. Lien, T. Y. Huang, M. Y. Chen, et al. 2010. A recombinant lipoprotein containing an unsaturated fatty acid activates NF-kappaB through the TLR2 signaling pathway and induces a differential gene profile from a synthetic lipopeptide. Mol. Immunol. 47: 2015-2021
34. Prajeeth, C. K., A. C. Jirmo, J. K. Krishnaswamy, T. Ebensen, C. A. Guzman, S. Weiss, H. Constabel, R. E. Schmidt, and G. M. N. Behrens. 2010. The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against coadministered and linked antigens. Eur. J. Immunol. 40: 1272-1283
35. Nguyen, D. T., L. De Witte, M. Ludlow, S. Yuksel, K. H. Wiesmuller, T. B. Geijtenbeek, A. D. Osterhaus, and R. L. De Swart. 2010. The synthetic bacterial lipopeptide Pam3CSK4 modulates respiratory syncytial virus infection independent of TLR activation. PLoS Pathog. 6: E1001049
36. Kiura, K., H. Kataoka, T. Nakata, T. Into, M. Yasuda, S. Akira, N. Inoue, and K. Shibata. 2006. The synthetic analogue of mycoplasmal lipoprotein FSL-1 induces dendritic cell maturation through Toll-like receptor 2. FEMS Immunol. Med. Microbiol. 46: 78-84
37. Khan, S., M. S. Bijker, J. J. Weterings, H. J. Tanke, G. J. Adema, T. Van Hall, J. W. Drijfhout, C. J. Melief, H. S. Overkleeft, G. A.Van Der Marel, et al. 2007. Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J. Biol. Chem. 282: 21145-21159
38. Shamsul, H. M., A. Hasebe, M. Iyori, M. Ohtani, K. Kiura, D. Zhang, Y. Totsuka, and K. Shibata. 2010. The Toll-like receptor 2 (TLR2) ligand FSL-1 is internalized via the clathrin-dependent endocytic pathway triggered by CD14 and CD36 but not by TLR2. Immunology 130: 262-272
39. Triantafilou, M., M. Manukyan, A. Mackie, S. Morath, T. Hartung, H. Heine, and K. Triantafilou. 2004. Lipoteichoic acid and toll-like receptor 2 internalization and targeting to the Golgi are lipid raft-dependent. J. Biol. Chem. 279: 40882-40889
40. Renaudet, O., G. Dasgupta, I. Bettahi, A. Shi, A. B. Nesburn, P. Dumy, and L. BenMohamed. 2010. Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity. PLoS ONE 5: E11216
41. Vonderheit, A., and A. Helenius. 2005. Rab7 associates with early endosomes to mediate sorting and transport of Semliki forest virus to late endosomes. PLoS Biol. 3: E233
42. Chen, L., and M. Jondal. 2009. TLR9 activation increases TAP-independent vesicular MHC class I processing in vivo. Scand. J. Immunol. 70: 431-438
43. Crespo, M. I., E. R. Zacca, N. G. Núñez, R. P. Ranocchia, M. Maccioni, B. A. Maletto, M. C. Pistoresi-Palencia, and G. Morón. 2013. TLR7 triggering with polyuridylic acid promotes cross-presentation in CD8a+ conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell surface. J. Immunol. 190: 948-960
44. Boes, M., J. Cerny, R. Massol, M. Op den Brouw, T. Kirchhausen, J. Chen, and H. L. Ploegh. 2002. T-cell engagement of dendritic cells rapidly rearranges MHC class II transport. Nature 418: 983-988
45. Galperin, E., and A. Sorkin. 2008. Endosomal targeting of MEK2 requires RAF, MEK kinase activity and clathrin-dependent endocytosis. Traffic 9: 1776-1790
46. Teis, D., N. Taub, R. Kurzbauer, D. Hilber, M. E. De Araujo, M. Erlacher, M. Offterdinger, A. Villunger, S. Geley, G. Bohn, et al. 2006. p14-MP1-MEK1 signaling regulates endosomal traffic and cellular proliferation during tissue homeostasis. J. Cell Biol. 175: 861-868
47. Robertson, S. E., S. R. Setty, A. Sitaram, M. S. Marks, R. E. Lewis, and M. M. Chou. 2006. Extracellular signal-regulated kinase regulates clathrinindependent endosomal trafficking. Mol. Biol. Cell 17: 645-657
48. Fang, L., H. M. Wu, P. S. Ding, and R. Y. Liu. 2014. TLR2 mediates phagocytosis and autophagy through JNK signaling pathway in Staphylococcus aureus-stimulated RAW264.7 cells. Cell. Signal. 26: 806-814
49. Bhattacharya, M., N. Ojha, S. Solanki, C. K. Mukhopadhyay, R. Madan, N. Patel, G. Krishnamurthy, S. Kumar, S. K. Basu, and A. Mukhopadhyay. 2006. IL-6 and IL-12 specifically regulate the expression of Rab5 and Rab7 via distinct signaling pathways. EMBO J. 25: 2878-2888